Form 13-F position report

CERO THERAPEUTICS HLDGS INC

Reported by Schonfeld Strategic Advisors LLC

CEROW CUSIP 71902K113 Manager CIK 0001665241

Reported 15,000 shares, down 5,000 (25.0%) from the prior quarter.

Reported value -77.9%; share count -25.0% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 15,000 Quarter-end amount reported
Reported value $301 Fair value at quarter end
Consecutive quarters held 9 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-06-30 4000
2022-09-30 3000
2022-12-31 1552
2023-03-31 1441
2023-06-30 2356
2023-09-30 2389
2023-12-31 917
2024-03-31 1364
2024-06-30 301
2024-09-30 76
2024-12-31 124
2025-03-31 217
2025-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for CERO THERAPEUTICS HLDGS INC held by Schonfeld Strategic Advisors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2025 Reduced 0 -15,000 (-100.0%) 0 $0 2025-08-14
Q1 2025 Unchanged 15,000 0 (0.0%) < 0.01% $217 2025-05-15
Q4 2024 Unchanged 15,000 0 (0.0%) < 0.01% $124 2025-02-14
Q3 2024 Unchanged 15,000 0 (0.0%) < 0.01% $76 2024-11-14
Q2 2024 Reduced 15,000 -5,000 (-25.0%) < 0.01% $301 2024-08-14
Q1 2024 Reduced 20,000 -13,373 (-40.1%) < 0.01% $1,364 2024-05-15
Q4 2023 Unchanged 33,373 0 (0.0%) < 0.01% $917 2024-02-14
Q3 2023 Reduced 33,373 -2,627 (-7.3%) < 0.01% $2,389 2023-11-14
Q2 2023 Unchanged 36,000 0 (0.0%) < 0.01% $2,356 2023-08-14
Q1 2023 Unchanged 36,000 0 (0.0%) < 0.01% $1,441 2023-05-15
Q4 2022 Unchanged 36,000 0 (0.0%) < 0.01% $1,552 2023-02-14
Q3 2022 Unchanged 36,000 0 (0.0%) < 0.01% $3,000 2022-11-14
Q2 2022 New 36,000 +36,000 (0.0%) < 0.01% $4,000 2022-08-15

Who else reported the position

39 managers reported CERO THERAPEUTICS HLDGS INC for Q2 2024.

Managers reporting CERO THERAPEUTICS HLDGS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Atalaya Capital Management LP Reduced 424,867 -133 0.02% $8,497,000 11 qtrs
Context Capital Management LLC Unchanged 122,013 0 < 0.01% $2,452,000 10 qtrs
Silver Rock Financial LP Unchanged 12,224 0 < 0.01% $246,000 7 qtrs
HIGHBRIDGE CAPITAL MANAGEMENT LLC Added 829,598 +1,054 < 0.01% $16,592 11 qtrs
COWEN AND COMPANY LLC Added 687,068 +48,467 < 0.01% $13,810 7 qtrs
CANTOR FITZGERALD L P Unchanged 441,048 0 < 0.01% $8,865 11 qtrs
Periscope Capital Inc Reduced 427,634 -163,866 < 0.01% $8,595 10 qtrs
MMCAP International Inc SPC Unchanged 375,000 0 < 0.01% $7,538 11 qtrs
Saba Capital Management L P Unchanged 295,913 0 < 0.01% $5,948 11 qtrs
Linden Advisors LP Unchanged 249,999 0 < 0.01% $5,625 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
*W EXP 02/13/202

Voting authority reported

Sole
0
Shared
0
None
15,000

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.